Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Tempus AI (TEM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Tempus AI — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $300.02 (market cap $39.89B), while Tempus AI trades at $57.84 (market cap $10.46B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 3.8× Tempus AI's market cap, and Tempus AI is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | TEM | |
|---|---|---|
Market Cap | $39.89B | $10.46B |
Sector | Health | Broad Market / Factor |
52-Week High | $491.22 | $103.25 |
52-Week Low | $278.09 | $42.37 |
Enterprise Value | $38.15B | $11.14B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Tempus AI (TEM) trades at $58.23, down 5.26% for the day, as the precision medicine technology company continues to show strong revenue growth but significant losses. The stock maintains a bullish technical signal with support at $58 and resistance at $64, while analysts remain optimistic with 61.5% buy ratings and a $63.50 consensus target. Recent FDA approvals for diagnostic tests and expanding AI platform capabilities provide growth catalysts despite ongoing operational losses.
The investment case hinges on Tempus's unique healthcare data platform and AI capabilities driving long-term growth, though substantial GAAP losses and negative cash flow from operations present near-term execution risks. With revenue projected to reach $1.4B in 2026 but net losses widening to $303M, the stock offers asymmetric upside if the company can achieve profitability while maintaining its 25%+ growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Tempus AI
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →
